ESMO 2021: PRODIGE 24 Trial
Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6
Highlights on gemcitabine vs mFOLFIRINOX in resected pancreatic cancer: PRODIGE 24/CCTG PA6
A new approach to cancer therapy shows potential to transform the commonly used chemotherapy drug…
Bladder preservation with trimodality therapy can be a safe and effective alternative to cystectomy for…
Pancreatic cancer carries a poor prognosis, and it often goes undetected until advanced stages. A…
Scientists have found a way to target and knock out a single protein that they…
A frontline chemotherapy drug given to patients with pancreatic cancer is made less effective because…
Mice with pancreatic cancer that were treated with a naturally occurring constituent of medicinal cannabis…
A combination of two chemotherapy drugs – gemcitabine and capecitabine – should be the new standard of care for…
A European phase III trial, one of the largest ever conducted in pancreatic cancer, showed…
A common flu virus could be used to overcome patients’ resistance to certain cancer drugs…